14-alpha demethylase inhibitors - Pipeline Insight, 2024

14-alpha demethylase inhibitors - Pipeline Insight, 2024

DelveInsight’s, “14-Alpha Demethylase Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in 14-Alpha Demethylase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

14-Alpha Demethylase Inhibitors Understanding

14-Alpha Demethylase Inhibitors: Overview

Sterol 14alpha-demethylase (CYP51) is the most widely distributed of all members of the cytochrome P450 gene superfamily and the only CYP family found in both prokaryotes and eukaryotes. It is well known as a drug target for microbial pathogenic infections.

Function - The biological role of this protein is also well understood. The demethylated products of the CYP51 reaction are vital intermediates in pathways leading to the formation of cholesterol in humans, ergosterol in fungi, and other types of sterols in plants. These sterols localize to the plasma membrane of cells, where they play an important structural role in the regulation of membrane fluidity and permeability and also influence the activity of enzymes, ion channels, and other cell components that are embedded within.

14-Alpha Demethylase Inhibitors – These are the compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived antifungal agents act through this mechanism. Azoles are currently the most popular class of antifungals used in both agricultural and medical settings. These compounds bind as the sixth ligand to the heme group in CYP51, thereby altering the structure of the active site and acting as noncompetitive inhibitors. The effectiveness of imidazoles and triazoles (common azole subclasses) as inhibitors of 14α-demethylase have been confirmed through several experiments.

14-Alpha Demethylase Inhibitors Emerging Drugs Chapters

This segment of the 14-Alpha Demethylase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

14-Alpha Demethylase Inhibitors Emerging Drugs

• Oteseconazole: Mycovia Pharmaceuticals

Oteseconazole (VT-1161) is a novel, investigational oral therapy in late-stage clinical development for the treatment of recurrent vulvovaginal candidiasis (RVVC). Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations. The drug is in preregistration stage for the treatment of Vulvovaginal candidiasis.

• Isavuconazonium: Basilea Pharmaceutica

Isavuconazole is an intravenous and oral azole antifungal and the active agent of the prodrug isavuconazonium sulfate. Isavuconazole is approved in the United States for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis. The drug is currently in phase 3 stage of development for the treatment of Candidiasis.

Further product details are provided in the report……..

14-Alpha Demethylase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different 14-Alpha Demethylase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on 14-Alpha Demethylase Inhibitors

There are approx. 12+ key companies which are developing the 14-Alpha Demethylase Inhibitors. The companies which have their 14-Alpha Demethylase Inhibitors drug candidates in the most advanced stage, i.e. preregistration include, Mycovia Pharmaceuticals.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

14-Alpha Demethylase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

14-Alpha Demethylase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 14-Alpha Demethylase Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 14-Alpha Demethylase Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence 14-Alpha Demethylase Inhibitors R&D. The therapies under development are focused on novel approaches for 14-Alpha Demethylase Inhibitors.

14-Alpha Demethylase Inhibitors Report Insights

• 14-Alpha Demethylase Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

14-Alpha Demethylase Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing 14-Alpha Demethylase Inhibitors drugs?
• How many 14-Alpha Demethylase Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for 14-Alpha Demethylase Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the 14-Alpha Demethylase Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for 14-Alpha Demethylase Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mycovia Pharmaceuticals
• Basilea Pharmaceutica
• Hill Dermaceuticals
• Zambon
• Pulmocide
• Angelini Pharmaceuticals
• Biolab Sanus Farmaceutica
• Astellas Pharma
• Basilea Pharmaceutica
• Pulmatrix
• Seren Pharmaceuticals
• Merck & Co
• Laboratoires SMB
• ProFem

Key Products

• Oteseconazole
• Isavuconazonium
• Miconazole
• ZP 059
• PC-945
• Benzydamine/econazole
• BL-123
• BAL 4815
• PUR 1900
• Fosravuconazole
• Posaconazole
• ITZ DPI
• Prof-001